Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.


BACKGROUND Preclinical and preliminary clinical data indicate that ch14.18, a monoclonal antibody against the tumor-associated disialoganglioside GD2, has activity against neuroblastoma and that such activity is enhanced when ch14.18 is combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-2. We conducted a study to… (More)
DOI: 10.1056/NEJMoa0911123


5 Figures and Tables

Blog articles referencing this paper